Sohan Chitlange

Dr. Sohan Chitlange


Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 November 2021 in Mini-Reviews in Medicinal Chemistry
Verified
Journal Article
Closed access
PDF file
PKPrajakta B. Kothawade
Prajakta B. Kothawade
ATAsha B Thomas
Asha B Thomas
SCSohan Chitlange
Sohan Chitlange
Background: Hyperlipidemia is characterized by high level of cholesterol and triglycerides in blood. Various classes of drugs like statins, fibrates, niacin etc. are used for treatment of hyperlipidaemia. Objective: Niacin, which is one of the beneficial anti-hyperlipidemic agents, helps to lower LDL cholesterol by 20 to 40% and causes increase of HDL cholesterol by 20 to 35%. However cutaneous flushing, loss of glucose tolerance, liver toxicity are the reported side effects of niacin therapy responsible for decreased patient compliance. Very recently, the G protein coupled receptor (GPCR); GPR109A located on the adipocytes has been identified as the receptor for activation of niacin. Method: In-vitro studies have demonstrated that GPR109A receptor having high affinity for niacin. The present review attempts to provide a systematic presentation of the various chemical classes of compounds that have been reported as novel niacin receptor agonists including pyrazole-3-carboxylic acids, urea derivatives, anthranilic acids, biaryl anthranilides, tetrahydro anthranilic acid, xanthines, barbituric acid, bicyclic pyrazole carboxylic acids, pyrido pyrimidinones, pyrazolyl propionyl cyclohexenamides, pyrazole acids etc. Results: As the design of GPR109A receptor agonists offers a promising solution for treatment of dyslipidemia, this review will be beneficial for medicinal and drug discovery chemists to expediate the process of discovery of new class of antihyperlipidemic agent with favorable lipid lowering profile with increase in HDL levels. Conclusion: This review explains about novel GPR109A receptor agonist for the treatment of dyslipidemia.

11 November 2022 in Cosmetics
Verified
Journal Article
Open access
PDF file
KPKomal Padule
Komal Padule
SSSonali Shinde
Sonali Shinde
SCSohan Chitlange
Sohan Chitlange
Prabhanjan S GiramPrabhanjan S Giram
Prabhanjan S Giram
DNDheeraj Nagore
Dheeraj Nagore
Polymer, lipid, and natural protein-based hair care nanocarriers are in preclinical testing. Nanomedicine has enhanced therapeutic efficacy and decreased side effects. This review examines herbal nanomedicine for hair care. We also reviewed the hair cycle, its morphology, and the mechanisms of herbal-based medicine that regulate the hair cycle to treat hair loss. Nano-formulations have better solubility, permeability, therapeutic efficacy, and prolonged distribution than standard herbal medicines. This review also discussed the nanotechnology barrier and nano formulations for hair loss and growth and includes a recent herbal nanomedicine study. Researchers interested in using herbs to treat hair problems and clinically translating hair care products may find the results presented significant.

1 July 2009 in Journal of AOAC INTERNATIONAL
Verified
Journal Article
Open access
PDF file
SCSohan Chitlange
Sohan Chitlange
PKPrajakta S Kulkarni
Prajakta S Kulkarni
DPDada Patil
Dada Patil
BPBhushan Patwardhan
Bhushan Patwardhan
RNRabindra K Nanda
Rabindra K Nanda
Because Ayurvedic herbal preparations contain a myriad of compounds in complex matrixes, it is difficult to establish quality control standards for raw materials and to standardize finished Ayurvedic drugs. A novel, accurate, and valid fingerprint method was developed using HPLC for quality control of a traditional Ayurvedic Arjuna churna formulation, which is used as a cardiotonic drug. Comprehensive comparison of chromatograms of standardized formulation of Arjuna churna and marketed formulations revealed eight characteristic peaks in chromatograms, which unambiguously confirmed the presence of authentic raw material used in the formulation on the basis of their retention time values and UV data. An HPLC fingerprint was also developed for total sapogenins present in Terminalia arjuna. The six common peaks observed in chromatograms of isolated sapogenins, standardized formulations, and marketed formulations can serve as a quality control tool for qualitative estimation of total saponin glycosides present in an Arjuna churna formulation.

4 July 2017 in Analytical Chemistry Letters
Verified
Journal Article
Closed access
SCSohan Chitlange
Sohan Chitlange
DRDiptee G. Rawat
Diptee G. Rawat
SGSejal P. Gandhi
Sejal P. Gandhi
A simple, accurate, precise and economical HPTLC and UV method has been developed and validated for the estimation of teneligliptin hydrobromide hydrate (THH) in bulk and tablet dosage form. The chromatographic method employed pre-coated silica gel 60F254 plates using toluene: methanol: triethylamine (8:2:0.2 v/v/v) as mobile phase. The plates were developed to a distance of 8.0 cm at ambient temperature. Experimental conditions such as band size, chamber saturation time, migration of solvent front, slit width, etc were critically studied and the optimum conditions were selected. A TLC scanner set at 254 nm was used for direct evaluation of the chromatograms in reflectance/absorbance mode. The system was found to give good result for Teneligliptin at Rf 0.51. The calibration plot was found linear between concentration range 0.5-3 μg/ band and r2 = 0.9993. Method was validated according to the ICH guidelines. In stability testing, teneligliptin was found susceptible to alkali hydrolysis and oxidatative degradation. Because the method could effectively separate the drug from its degradation products, it can be used as a stability indicating method. A UV spectrophotometric method was also developed using methanol as solvent at λ max 247 nm. Beer's law was obeyed in the concentration range of 5-50 μg/ml and r2 = 0.9997. The proposed method was validated according to the ICH guidelines. Therefore, both the methods and stress degradation study can be used for routine quality control analysis of Teneligliptin in bulk and pharmaceutical formulation.

23 September 2010 in Preparative Biochemistry & Biotechnology
Verified
Journal Article
Closed access
SCSohan Chitlange
Sohan Chitlange
AMAmir I. Mulla
Amir I. Mulla
GPGanesh R. Pawbake
Ganesh R. Pawbake
SWSagar B. Wankhede
Sagar B. Wankhede
A stability-indicating thin layer chromatographic (TLC) method for determination of dexrabeprazole (DEX) and domperidone (DOM) in combined dosage form has been developed and validated. The mobile phase selected was acetone:toluene:methanol (4.5:4.5:0.5, v/v/v) with ultraviolet (UV) detection at 285 nm. The retention factors for DEX and DOM were found to be 0.49 ± 0.02 and 0.24 ± 0.03, respectively. The method was validated with respect to linearity, accuracy, precision, and robustness. The linearity range for DEX was 50–350 ng/band (r 2 = .9960) and for DOM was 100–700–n /band (r 2 = .9982), respectively. The method was successfully applied for the analysis of drugs in pharmaceutical formulation.

1 September 2021 in Turkish Journal of Pharmaceutical Sciences
Verified
Journal Article
Closed access
RKRupali Kale
Rupali Kale
PSPratiksha Shete
Pratiksha Shete
DDDattatray Doifode
Dattatray Doifode
SCSohan Chitlange
Sohan Chitlange
This study was aimed to develop and validate the use of reverse-phase high pressure liquid chromatographic method for the estimation of simvastatin (SIM) and mupirocin (MUP) simultaneously. The chromatographic method developed is optimized for flow rate with the column, solvent, and buffer used and mobile phase ratio, molarity, and pH. The validation of the optimized method and the forced degradation studies of both drugs (under acidic, alkaline, oxidation, heat, light, and neutral conditions) were conducted following the The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use guidelines. Kromasil C18 column (250 mm × 4.6 mm, 5 µm) with ultraviolet detection at 224 nm and acetonitrile/phosphate buffer (30 mM, 70:30 v/v, pH 3.5; adjustment done using orthophosphoric acid) as mobile phase at a flow rate of 1.1 mL/min were observed to provide a good resolution for MUP and SIM at retention times of 2.32±0.008 and 13.55±0.254 min, respectively, with high accuracy (percent recovery was 99.69±0.82 for MUP and 101.10±0.02 for SIM) and linearity in the range of 5-30 µg/mL (r2: 0.9969 for MUP and r2: 0.9959 for SIM). The diagnostic limit and the lower limit of determination were 0.771±0.234 and 2.338±0.246 μg/mL for MUP and 0.595±0.282 and 1.803±0.334 µg/mL for SIM, respectively. The validated method was used to understand the degradation behavior of both drugs after the forced degradation studies. The analytical method developed is determined to be specific, sensitive, precise, and accurate for the estimation of MUP and SIM simultaneously in the combined dosage form.